Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
Hartomo TB, Kozaki A, Hasegawa D, Van Huyen Pham T, Yamamoto N, Saitoh A, Ishida T, Kawasaki K, Kosaka Y, Ohashi H, Yamamoto T, Morikawa S, Hirase S, Kubokawa I, Mori T, Yanai T, Hayakawa A, Takeshima Y, Iijima K, Matsuo M, Nishio H, Nishimura N.
Hartomo TB, et al. Among authors: hayakawa a.
Oncol Rep. 2013 Apr;29(4):1629-36. doi: 10.3892/or.2013.2286. Epub 2013 Feb 12.
Oncol Rep. 2013.
PMID: 23417100